Halt Medical commences enrollment in uterine fibroid study

The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids.  "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco. 

Fibroids are benign tumors of the uterus that cause serious, debilitating symptoms including heavy menstrual bleeding, severe cramping, urinary problems, and painful intercourse. Currently the only cure that the gynecologist can offer to patients with fibroids involves major surgery.  "Each year nearly 250,000 women in the US undergo radical surgery to remove their entire uterus rather than to continue suffering with their fibroid symptoms," according to Mr. DeLonzor.  About 8 million women have fibroids, or leiomyomas of the uterus.  "So many lives are impacted in some way by fibroids.  It's no surprise that a clinical study of an outpatient procedure which targets the fibroids while sparing the uterus would gain such widespread attention from the media."  

Details of who may qualify for the Halt Uterine Fibroid Study and participating clinical sites are available through the National Institutes of Health at:  clinicaltrials.gov/ct2/show/NCT00874029

SOURCE Halt Medical, Inc.